Dl-3-n-butylphthalide is effective for demyelination: a case-combined study.
Demyelinating diseases is common in neurology department, but its treatment is still not clear. A 40-year-old male who was addicted in heroin was hospitalized and presented worsening altered mental status in hospital. Brain magnetic resonance imaging (MRI) revealed a symmetrical diffuse long T1 and long T2 time abnormalities in the white matter of cerebral hemispheres which indicated demyelination. High-dose intravenous methylprednisolone was not effective as expected. However, after treatment with intravenous Dl-3-n-butylphthalide for 7 days, the patient's symptoms and features of electroencephalogram (EEG) and MRI improved. Hence, ethidium bromide was used in a rat model to evaluate the positive effects of Dl-3-n-butylphthalide in demyelinating diseases. The results indicated that Dl-3-n-butylphthalide prevented white matter from demyelinating by regulating apoptosis through multiple approaches.